In a phase II clinical trial of high-risk PCa patients receiving ADT plus docetaxel or ADT plus abiraterone as neoadjuvant therapy, with a median follow-up time of 30 months, the study found that [68 Ga] PSMA PET/CT was an ideal tool for monitoring response to neoadjuvant therapy (Chen et al., 2023). Here, FOLH1 is linked to posterior cortical atrophy.